tradingkey.logo
tradingkey.logo
Search

Celldex Therapeutics Inc

CLDX
Add to Watchlist
37.620USD
-1.360-3.49%
Market hours 09/18, 13:29ET
2.95BMarket Cap
LossP/E TTM

Celldex Therapeutics Inc (CLDX) Stock Analysis

Celldex Therapeutics Inc's Score

Score
6.76/10
The current financial score of Celldex Therapeutics Inc is 5.71. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 22.00K, representing a year-over-year decrease of 96.99%, while its net profit experienced a year-over-year decrease of 29.86%.
The current valuation score of Celldex Therapeutics Inc is 8.02. Its current P/E ratio is -9.13, which is -38.76% below the recent high of -5.59 and -116.75% above the recent low of -19.80.
The current earnings forecast score of Celldex Therapeutics Inc is 8.53. The average price target is 58.38, with a high of 100.00 and a low of 38.00.
The current price momentum score of Celldex Therapeutics Inc is 3.52. Currently, the stock price is trading between the resistance level at 41.79 and the support level at 36.51, making it suitable for range-bound swing trading.
The current institutional shareholding score of Celldex Therapeutics Inc is 10.00. The latest institutional shareholding proportion is 96.30%, representing a quarter-over-quarter decrease of 26.99%. The largest institutional shareholder is Ken Fisher, holding a total of 985.68K shares, representing 0.01% of shares outstanding, with 25.72% increase in holdings.
The current risk assessment score of Celldex Therapeutics Inc is 7.17. The company's beta value is 0.96. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.

Celldex Therapeutics Inc (CLDX) Techinical, Sentiment, SWOT Analysis

Analyst Rating

Based on 15 analysts
Current RatingBuy
Target Price58.385
Upside Space+51.61%

Support & Resistance

Relevant data have not been disclosed by the company yet.

Industry at a Glance

Industry Ranking
62 / 377
Overall Ranking
116 / 4217
Industry
Biotechnology & Medical Research

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Positive+

Celldex Therapeutics Inc Highlights

StrengthsRisks
Growing
The company is in a growing phase, with the latest annual income totaling USD 1.54M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 1.54M.
Fairly Valued
The company’s latest PE is -9.13, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 75.58M shares, decreasing 7.88% quarter-over-quarter.
Held by Ken Fisher
Star Investor Ken Fisher holds 985.68K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.27.

FAQs

How does TradingKey generate the Stock Score of Celldex Therapeutics Inc?

The TradingKey Stock Score provides a comprehensive assessment of Celldex Therapeutics Inc based on 34 indicators derived from over 100 underlying data points.
These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Celldex Therapeutics Inc’s performance and outlook.

How do we generate the financial health score of Celldex Therapeutics Inc?

To generate the financial health score of Celldex Therapeutics Inc, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns.
By integrating these comprehensive data, the financial health score not only reflects Celldex Therapeutics Inc's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Celldex Therapeutics Inc.

How do we generate the company valuation score of Celldex Therapeutics Inc?

To generate the company valuation score of Celldex Therapeutics Inc, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Celldex Therapeutics Inc’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value.
By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Celldex Therapeutics Inc’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Celldex Therapeutics Inc.

How do we generate the earnings forecast score of Celldex Therapeutics Inc?

To calculate the earnings forecast score of Celldex Therapeutics Inc, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:
Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.
Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.
By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.
Comparing these indicators against peers provides context for the stock’s performance and helps anchor more realistic expectations.
These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Celldex Therapeutics Inc’s future.

How do we generate the price momentum score of Celldex Therapeutics Inc?

When generating the price momentum score for Celldex Therapeutics Inc, we examine momentum indicators including support and resistance levels as well as volume metrics.
Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.
This comprehensive approach can reflect market sentiment and enable rational forecasts of Celldex Therapeutics Inc’s prices. A higher score indicates a more stable short-term price trend for Celldex Therapeutics Inc.

How do we generate the institutional confidence score of Celldex Therapeutics Inc?

To generate the institutional confidence score of Celldex Therapeutics Inc, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Celldex Therapeutics Inc’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Celldex Therapeutics Inc.

How do we generate the risk management score of Celldex Therapeutics Inc?

To assess the risk management score of Celldex Therapeutics Inc, we examine multiple key indicators related to returns, risk, volatility, and liquidity.
The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.
These indicators together provide a multi-dimensional understanding of Celldex Therapeutics Inc’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Celldex Therapeutics Inc.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.